Regeneron Otarmeni Gene Therapy FDA Hearing Breakthrough
TARRYTOWN, N.Y., April 23, 2026 Regeneron Pharmaceuticals has achieved a landmark milestone as the U.S. Food and Drug Administration...
Gene Therapy
Advertisement
Dyno AI Capsid Licensed by Astellas for Gene Therapy
WATERTOWN, Mass., April 8, 2026 Dyno Therapeutics, Inc. has announced that Astellas Pharma has exercised its option to license...
Sanofi Lunsekimig Shows Strong Phase 2 Results in Asthma
Paris, France, April 7, 2026 Phase 2 Success Across Respiratory Indications In a major advancement for respiratory disease therapeutics,...
Renovare Therapeutics Launches with $33.5M ARPA-H Support
Boulder, Colorado, USA, April 6, 2026 $33.5M ARPA-H Funding Accelerates Regenerative Pipeline In a major boost to regenerative medicine...
Affinia Therapeutics Wins Canada Nod for AFTX-201 Trial
Waltham, Massachusetts, USA, April 6, 2026 Health Canada Approval Marks Key Clinical Milestone In a significant development for cardiovascular...
Advertisements
CU Anschutz Secures FDA IND for CAR T-Cell Therapy
AURORA, Colo., April 2, 2026 The University of Colorado Anschutz Medical Campus Gates Institute announced it has received U.S....
Ultragenyx Advances UX016 Into Clinical Trials for GNEM
NOVATO, Calif., March 30, 2026 Ultragenyx Pharmaceutical Inc. has announced that the U.S. Food and Drug Administration (FDA) has...
Ultragenyx Advances UX111 Gene Therapy Toward Approval
NOVATO, Calif., April 2, 2026 Ultragenyx Pharmaceutical Inc. has reached a significant regulatory milestone as the U.S. Food and...
Thermo Fisher Launches Compleo System for Cell Therapy
WALTHAM, Mass., USA — April 2, 2026 Thermo Fisher Scientific Inc. has announced the global launch of the Gibco™...
Ocugen Completes Dosing in Phase 2/3 Stargardt Trial
MALVERN, Pa., USA — April 1, 2026 Ocugen, Inc. has announced the early completion of dosing in its Phase...
Advertisement
